As cases of COVID-19 spread across the globe, U.S. regulatory agencies respond to false product claims surrounding the outbreak with a wave of company warning letters.
Losing its patience with the FDA, a bipartisan bill was introduced to allow CBD into foods and supplements.
Who is the Obi-Wan Kenobi of the hemp CBD supplements alliance? In other words, what will 2020 bring in terms of consolidation and regulation within the hemp industry? Here are some educated predictions.
This week, the influential watchdog organization's senior vice president for government affairs implored the House Committee on Energy and Commerce to increase FDA's authority in the personal care sphere.
Organic sector and Capitol Hill show strong support for rule in final comments.
Congress said to legalize it, and left it to FDA to figure out details. FDA's position: pound sand.
Motion for summary judgment states USDA acted unlawfully in withdrawing livestock standards.
Lawmakers seek a policy of enforcement discretion but that wouldn’t address the underlying problem facing the hemp industry—namely FDA’s position that CBD cannot be marketed in a dietary supplement.
Former Food and Drug Administration Commissioner Scott Gottlieb lays out a pharma-friendly pathway for CBD in a Washington Post op-ed.
Retail excitement about the hemp CBD market is obvious, even if the regulatory hurdles aren't always as clear.